<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02120404</url>
  </required_header>
  <id_info>
    <org_study_id>P120912</org_study_id>
    <secondary_id>2013-005174-22</secondary_id>
    <nct_id>NCT02120404</nct_id>
  </id_info>
  <brief_title>Pilot Phase II Study: Hemodynamic Tolerance and Anti-inflammatory Effects of Esmolol During the Treatment of Septic Shock</brief_title>
  <acronym>THANE</acronym>
  <official_title>Pilot Phase II Study: Hemodynamic Tolerance and Anti-inflammatory Effects of Esmolol During the Treatment of Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is :&#xD;
&#xD;
      - to evaluate the hemodynamic tolerance of esmolol titrated to obtain a lowering of heart&#xD;
      rate of 10% or 20%.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During septic shock, the consequences of treatment by a β1-blocker on inflammation and&#xD;
      cardiovascular variability are unknown. The use of esmolol should have positive effects on&#xD;
      inflammation and hemodynamic tolerance. These effects are probably dose-dependent.&#xD;
&#xD;
      The study will enroll adult patients hospitalized in ICU, for severe septic shock requiring&#xD;
      treatment by a vasopressor.&#xD;
&#xD;
      A total of 45 patients will be included. Among these 45 patients, 15 patients will be&#xD;
      randomized in the control group. 30 patients will be randomized to Esmolol with the objective&#xD;
      to decrease heart rate by 10% (Group G10, n=15) or 20% (Group G20, n=15). Esmolol will be&#xD;
      administered for 24 hours.&#xD;
&#xD;
      This multicenter study will be performed in 3 investigation sites.&#xD;
&#xD;
      The following parameters will be evaluated at different moments during the 28 days follow up&#xD;
      of each patient, mainly:&#xD;
&#xD;
        -  Origin of sepsis, SOFA score.&#xD;
&#xD;
        -  Hemodynamic parameters will be continuously recorded for the 24 hours of experimental&#xD;
           period.&#xD;
&#xD;
        -  Cardiovascular variability (arterial pressure and heart rate) will be recorded for 24&#xD;
           hours.&#xD;
&#xD;
        -  3 echocardiograms at H0, H12 and H24 will be performed.&#xD;
&#xD;
        -  Biological parameters will be sampled at H0, H6, H12 and H24: They include standard&#xD;
           biological parameters (Urea, Creatinin, Bilirubin,……) and specific parameters&#xD;
           (catecholamines, vasopressin, insulin, cortisol, proinflammatory cytokines and&#xD;
           anti-inflammatory cytokines. Dosages will be performed only at H0, H12 and H24 in order&#xD;
           to study:&#xD;
&#xD;
             -  The expression of adrenergic receptors and their genetic polymorphisms on&#xD;
                circulating immune cells.&#xD;
&#xD;
             -  The Th1/Th2 balance in immune cells.&#xD;
&#xD;
      Each patient will be followed-up for 28 days.&#xD;
&#xD;
      The variation of MAP and of cardiac output induced by esmolol should not exceed 15% of&#xD;
      baseline values. If the variation is more important esmolol administration will be stopped&#xD;
      and the hemodynamical tolerance will be defined as poor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of hemodynamic parameters between 3 groups</measure>
    <time_frame>24 hours</time_frame>
    <description>3 groups: GC, G10 and G20.&#xD;
The hemodynamic tolerance will be considered as satisfactory if the variation of MAP and cardiac output induced by esmolol does not exceed 15% of baseline (H0).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunomodulatory effect</measure>
    <time_frame>24 hours</time_frame>
    <description>Immunomodulatory effect of esmolol will be evaluated notably by the ratio of IL6 / IL10.&#xD;
The decrease of this ratio in comparison with the value at baseline (H0) will be considered as an indicator of esmolol efficacy as immunomodulator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of number and severity of organ failures, between the 3 groups</measure>
    <time_frame>28 days</time_frame>
    <description>3 groups will be evaluated by SOFA score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of autonomic nervous system activity between the 3 groups</measure>
    <time_frame>24 hours</time_frame>
    <description>Power spectrum analysis of heart rate variability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of mortality in the 3 groups</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison in the 3 groups of the correlations between the biomarkers and the hemodynamic data</measure>
    <time_frame>24 hours</time_frame>
    <description>The biomarkers in plasma levels: cortisol, catecholamine, proinflammatory cytokines and anti-inflammatory cytokines.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Control group (GC)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group: no esmolol administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 10 (G10)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Esmolol titrated in order to reduce heart rate by 10% as compared to baseline heart rate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 20 (G20)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Esmolol titrated in order to reduce heart rate by 20% as compared to baseline heart rate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol administration</intervention_name>
    <description>Esmolol will be administered during 24 hours, beginning with a titration period to determine the minimal dose allowing to achieve the randomized heart rate reduction of 10% or 20%, as defined by randomization.&#xD;
Titration will be performed in sequences of increasing doses, beginning with 5 μg/kg/min as initial dose, and increasing by 5 μg/kg/min each 30 minutes until the target heart rate reduction is obtained. The maximum dose is 200 μg/kg/min.&#xD;
The titrated dose will be maintained for a total duration of 24 hours.</description>
    <arm_group_label>Group 10 (G10)</arm_group_label>
    <arm_group_label>Group 20 (G20)</arm_group_label>
    <other_name>BREVIBLOC 10 mg/ml</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient aged ≥ 18 years;&#xD;
&#xD;
          -  Patient with septic shock;&#xD;
&#xD;
          -  Patient with arterial catheter, central venous catheter with PVC and PiCCO;&#xD;
&#xD;
          -  Consent signed by patient. In the absence of a consent signed by patient himself, a&#xD;
             consent by a family member will be sought. As soon as possible, the patient will be&#xD;
             informed and asked to sign a consent for continuing of study;&#xD;
&#xD;
          -  Hemodynamic stability of patient during 1 hour without change in norepinephrine&#xD;
             dosage;&#xD;
&#xD;
          -  Treatment with noradrenaline for less than 48 hours.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Need of noradrenaline &gt; 3 mg/h;&#xD;
&#xD;
          -  Treatment with dobutamine;&#xD;
&#xD;
          -  Personal history of severe asthma;&#xD;
&#xD;
          -  Personal history of severe chronic obstructive pulmonary disease;&#xD;
&#xD;
          -  Personal history of pulmonary hypertension;&#xD;
&#xD;
          -  Personal history of second degree or third degree atrioventricular block without&#xD;
             pacemaker;&#xD;
&#xD;
          -  Personal history of sinoatrial block without pacemaker;&#xD;
&#xD;
          -  Chronic heart failure with ejection fraction &lt; 40%;&#xD;
&#xD;
          -  Severe atrioventricular nodal bradycardia (heart rate &lt; 70 bpm);&#xD;
&#xD;
          -  Mean arterial pressure &lt; 65 mm Hg;&#xD;
&#xD;
          -  Hypersensitivity to esmolol;&#xD;
&#xD;
          -  Prinzmetal angina;&#xD;
&#xD;
          -  Pheochromocytoma without treatment;&#xD;
&#xD;
          -  Pregnancy woman;&#xD;
&#xD;
          -  Breastfeeding woman;&#xD;
&#xD;
          -  Peripheral arterial disease;&#xD;
&#xD;
          -  Patient with pacemaker;&#xD;
&#xD;
          -  Chronic treatment with a beta blocker;&#xD;
&#xD;
          -  Concomitant treatment with bepridil, diltiazem, verapamil, amiodarone, propafenone,&#xD;
             Class Ia antiarrythmics (hydroquinidine, disopyramide) or baclofen;&#xD;
&#xD;
          -  Patient &lt; 18 years;&#xD;
&#xD;
          -  Patient under the care of a guardian;&#xD;
&#xD;
          -  Therapeutic futility;&#xD;
&#xD;
          -  Lack of medical insurance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Djillali ANNANE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICU, Hôpital Raymond Poincaré, 92380 Garches, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICU, Hôpital Raymond Poincaré</name>
      <address>
        <city>Garches</city>
        <state>Haute Des Seine</state>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 18, 2014</study_first_submitted>
  <study_first_submitted_qc>April 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2014</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>septic shock, hemodynamic tolerance, esmolol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

